The BRN2 transcription factor (POU3F2, N-Oct-3) has been implicated in development of the melanocytic lineage and in melanoma. Using a low calcium medium supplemented with stem cell factor, ¢broblast growth factor-2, endothelin-3 and cholera toxin, we have established and partially characterised human melanocyte precursor cells, which are unpigmented, contain immature melanosomes and lack L-dihydroxyphenylalanine reactivity. Melanoblast cultures expressed high levels of BRN2 compared to melanocytes, which decreased to a level similar to that of melanocytes when cultured in medium that contained phorbol ester but lacked endothelin-3, stem cell factor and ¢broblast growth factor-2. This decrease in BRN2 accompanied a positive L-dihydroxyphenylalanine reaction and induction of melanosome maturation consistent with melanoblast di¡erentiation seen during development. Culture of primary melanocytes in low calcium medium supplemented with stem cell factor, ¢broblast growth factor-2 and endothelin-3 caused an increase in BRN2 protein levels with a concomitant change to a melanoblast-like morphology. Synergism between any two of these growth factors was required for BRN2 protein induction, whereas all three factors were required to alter melanocyte morphology and for maximal BRN2 protein expression. These ¢nding implicate BRN2 as an early marker of melanoblasts that may contribute to the hierarchy of melanocytic gene control.
The BRN2 transcription factor (POU3F2, N-Oct-3) has been implicated in development of the melanocytic lineage and in melanoma. Using a low calcium medium supplemented with stem cell factor, ¢broblast growth factor-2, endothelin-3 and cholera toxin, we have established and partially characterised human melanocyte precursor cells, which are unpigmented, contain immature melanosomes and lack L-dihydroxyphenylalanine reactivity. Melanoblast cultures expressed high levels of BRN2 compared to melanocytes, which decreased to a level similar to that of melanocytes when cultured in medium that contained phorbol ester but lacked endothelin-3, stem cell factor and ¢broblast growth factor-2. This decrease in BRN2 accompanied a positive L-dihydroxyphenylalanine reaction and induction of melanosome maturation consistent with melanoblast di¡erentiation seen during development. Culture of primary melanocytes in low calcium medium supplemented with stem cell factor, ¢broblast growth factor-2 and endothelin-3 caused an increase in BRN2 protein levels with a concomitant change to a melanoblast-like morphology. Synergism between any two of these growth factors was required for BRN2 protein induction, whereas all three factors were required to alter melanocyte morphology and for maximal BRN2 protein expression. These ¢nding implicate BRN2 as an early marker of melanoblasts that may contribute to the hierarchy of melanocytic gene control. Key words: melanoma/POU/melanocyte/tyrosinase. J Invest Dermatol 121: 1150^1159, 2003 P OU domain DNA-binding transcription factors are developmental regulators of multiple cell lineages and represent a conserved family of proteins throughout metazoan evolution (Ryan and Rosenfeld, 1997; Dailey and Basilico, 2001) . The Class III factor BRN2 (also known as POU3F2 and N-Oct-3) has been implicated in the development of several neural and glial cell lineages, including neurons and astrocytes (Fujii and Hamada, 1993; Schreiber et al, 1994) , as well as the neural-crest-derived melanocytic lineage, owing to its expression in murine melanoblasts (Eisen et al, 1995) . BRN2 also appears to be important for development of malignant melanoma because its expression in human melanoma cell lines is much higher than in primary melanocytes (Cox et al, 1988; Thomson et al, 1993; Eisen et al, 1995) , and melanoma cell lines expressing antisense BRN2 lose the ability to form tumors in mice (Thomson et al, 1995) . Additionally, BRN2 ablated melanoma cells revert to a less mature cell type lacking many markers of di¡erentiated melanocytes such as tyrosinase (TYR)-related protein (TYRP) pigmentation genes and the microphthalmia associated transcription factor (Thomson et al, 1995) , implicating BRN2 in sustaining the melanocytic phenotype. Interestingly, expression of BRN2 can be modulated in human melanoma cell lines, with di¡erentiating agents decreasing expression and depigmentation agents increasing expression (Sturm et al, 1991) , implying a role for BRN2 in maintaining the undi¡erentiated melanocytic phenotype.
Melanoblasts are the neural-crest-derived precursor of the melanocytes. Their study is valuable for the analysis of basic mechanisms in cell di¡erentiation, for comparison with poorly di¡erentiated cells from melanoma, and for the molecular analysis of the many known genetic disorders of melanocyte development. Melanoblasts have been de¢ned as unpigmented cells that lack functional TYR, the critical enzyme of melanin synthesis (Hirobe, 1992; Sviderskaya et al, 1995) containing only immature melanosomes (Kawa et al, 2000) . However, others have de¢ned melanocytes as cells able to synthesize melanosomes (Jimbow et al, 1999) which mature through a four stage process, with Stage I^II melanosomes unable to synthesize melanin and hence considered immature, whereas Stage III^IV contain melanin (Marks and Seabra, 2001 ).
Expression of the melanogenic enzymes TYR, TYRP1, and dopachrome tautomerase is useful in identifying melanoblasts. Of these, dopachrome tautomerase is the earliest melanoblast marker in murine embryos, being detected at 10 d postcoitum, whereas Tyr and Tyrp1 are not expressed until 14.5 d postcoitum and pigment production is not visible until 16.5 d postcoitum (Steel et al, 1992) . In human embryos, melanoblasts have been detected by expression of another melanosomal protein SILV (determined by HMB-45 immunoreactivity) in the epidermis after 7 wk of gestation, with premelanosomes detectable at 10 wk (reviewed in Reedy et al, 1998) .
Recently, Nishimura et al (2002) demonstrated that murine melanoblasts reside in the lower permanent portion of the hair follicle and act as stem cells to supply melanocytes that provide melanin to the growing hair. Additionally, migration of melanoblasts from one hair follicle through the epidermis to follicles lacking melanoblasts can occur, where they assume the stem cell role in the new follicle. In hairless epidermis, melanoblasts di¡er-entiate to melanocytes which provide the surrounding keratinocytes with melanosomes for protection from ultraviolet radiation (Herlyn et al, 2000; Seiberg, 2001) .
Cultures of murine melanoblasts have been described previously (Sviderskaya et al, 1995; Kawa et al, 2000; Sviderskaya et al, 2001) and are capable of di¡erentiation in vitro to melanocytes. Several peptide growth factors are known to be required for melanocytic development in mouse and for the culture of both human and mouse melanocytes (Bohm et al, 1995; Moellmann and Halaban, 1998; Reedy et al, 1998; Goding, 2000; Halaban, 2000) . Conditions for melanoblast culture typically include these growth factors in the medium. Stem cell factor (SCF) acts as a chemotactic factor for migration of murine melanoblasts into hair follicles (Jordan and Jackson, 2000) and can mediate interactions with the environment by altering integrin expression (Scott et al, 1994) . SCF enhances murine melanoblast survival and proliferation in culture and can inhibit pigmentation (Reid et al, 1995; Sviderskaya et al, 2001 ). Endothelin-3 (EDN3) causes the di¡eren-tiation of chick neural crest cultures to melanocytic and glial precursor cells (Lahav et al, 1996; Lahav et al, 1998) ; however, proliferation of immortal murine melanoblasts is not a¡ected by removal of EDN3 (Sviderskaya et al, 2001) . Interestingly, murine melanoblast cultures from piebald mice, which carry mutations in the EDN3 receptor Ednrb, have impaired growth and di¡erentia-tion (Sviderskaya et al, 1998) .
Fibroblast growth factor-2 (FGF2) is a mitogen for melanocytes (Halaban et al, 1988a, b) and like SCF is required for murine melanoblast proliferation (Sviderskaya et al, 2001) . FGF2 also may be involved in melanoma progression, because adenovirally delivered FGF2 conferred melanoma-like growth characteristics to human melanocytes (Nesbit et al, 1999) . In combination with ultraviolet B it also induced lentiginous melanoma in skin reconstruction models (Berking et al, 2001) . The phorbol ester 12-Otetradecanoylphorbol-13 -acetate (TPA) is routinely used as a mitogen in melanocyte cultures to prolong survival (Arita et al, 2000; Halaban, 2000) . Importantly, FGF2, SCF, EDN3, and TPA have been classi¢ed as ''potent synergistic mitogens'' for human melanocyte growth owing to the convergence of signaling initiated by these growth factors on the mitogen-activated protein kinase pathway and activation of cAMP-responsive elementbinding protein (Bohm et al, 1995; Halaban, 2000) .
Conditions for the culture of primary human melanoblasts have yet to be described. Here, we report the establishment and partial characterization of primary human melanoblast cultures and demonstrate molecular and morphologic changes in response to di¡erent media conditions. Furthermore, we show that human melanoblasts express the BRN2 protein at high levels comparable to that seen in metastatic melanoma cell lines and in contrast to the low levels expressed in melanocytes. Reports describing the exquisite sensitivity of the levels of POU proteins in dimerization which subsequently determine stem cell fate (Niwa et al, 2000) and adult tissue speci¢c gene expression (Ryan and Rosenfeld, 1997) implicate the BRN2 molecule as a possible essential control mechanism in the melanocytic di¡erentiation pathway. Synergistic regulation of BRN2 levels by peptide growth factors within the melanocytic lineage may enable cell fate to be determined by an analogous dimerization mechanism (Smit et al, 2000) . For this reason, we have examined the response of BRN2 to peptide growth factors in human melanoblast and melanocyte cell cultures.
This project complies with the provisions contained in the National Statement on Ethical Conduct in Research Involving Humans and complies with the regulations governing experimentation on humans.
MATERIALS AND METHODS
Mammalian cell culture Throughout this article, ''melanoblasts'' refers to melanocytic cells established from neonatal foreskin tissue in melanoblast growth medium and ''MB:MC'' refers to melanoblasts grown in melanocyte growth medium for 1 wk before assay. Likewise, ''melanocytes'' refers to cells established from foreskin tissue in melanocyte medium and ''MC:MB'' refers to melanocytes grown in melanoblast medium for 1 wk before assay. Both melanoblasts and melanocytes were obtained from neonatal foreskin tissue, and melanocytes cultured as described with 10 ng per mL TPA and 0.6 mg per mL cholera toxin (Smith et al, 2001 ) after release of epidermal sheets from the dermis by Dispase II (Roche, Basel, Switzerland) treatment. For melanocytes, trypsin was neutralized by addition of RPMI 1640 medium plus 10% fetal bovine serum (FBS; CSL Biosciences, Victoria, Australia) or for melanoblasts MCBD 153 (Sigma Chemical Co., St. Louis, MO) medium containing 10% chelated FBS and 2% FBS. Melanoblasts were plated out in MCBD 153 medium containing 10% chelated FBS, 2% FBS, 2 mM glutamine, 1.66 mg per L cholera toxin, 10 ng per mL SCF (Sigma), 100 nM EDN3, and 2.5 ng per mL FGF2 (Nesbit et al, 1999) at 371C in 5% CO2/5%O2 . Chelated FBS was prepared by mixing 15 g of Chelex-100 (Sigma) per 500 mL of FBS for 1.5 h at 41C with gentle stirring. Culture medium for melanoma cell lines was 10% FBS in RPMI 1640. The MM96L c8 LC cell line was established by phenotypically ablating BRN2 expression using BRN2 antisense RNA (Thomson et al, 1995) . All culture media contained FBS of the same batch and contained penicillin (50 U/mL) and streptomycin (50 mg/mL). Primary murine neural crest cell lines were as described in Murphy et al (1991) . Fresh cultures were established according to Reid et al (1996) . Cultures that were Kit-negative contained less than 0.1% Kitpositive cells and were cultured in medium containing 10% FBS with no added growth factors. Cultures that were Kit-positive and unpigmented were cultured in the presence of SCF (Reid et al, 1995 (Reid et al, , 1996 and contained approximately 10% Kit-positive cells. Pigmented cultures that were Kit-positive contained at least 65% pigmented cells and were cultured in the presence of SCF, EDN3, and a-MSH (Reid et al, 1996) . Fresh neural crest cultures were harvested 2 wk after initiation of culture.
Transmission electron microscopy Cells were harvested and washed in PBS, before resuspension of cell pellets in 3% glutaraldehyde in 0.1 M phosphate bu¡er, pH 7.4. Samples were post¢xed in potassiumf erricyanide-reduced osmium tetroxide in phosphate bu¡er (1% osmium and 0.25% ferricyanide) and stained en bloc in 2% uranyl acetate.
Blocks were dehydrated in ascending concentrations of acetone and subsequently in¢ltrated and embedded in Spurr's resin. Sections were contrasted with lead citrate and viewed on a Hitachi H600 transmission electron microscope at 100 kV. temperature in 5% skim milk powder in phosphate-bu¡ered saline/0.05% Tween 20 (PBS-T), before incubation with primary antibody for 1.5 h at room temperature. Primary antibodies were anti-BRN2-C-terminal (anti-BRN2C) a⁄nity-puri¢ed rabbit polyclonal antibody (Smith et al, 1998) , anti-MART-1 (Dako Corporation, Carpinteria, CA) diluted 1:500 in 5% skim milk powder in PBS-T, or undiluted anti-TYR 5C13 (McEwan et al, 1988) or anti-TYRP1 B8G3 (Takahashi and Parsons, 1990) monoclonal supernatant. Secondary antibody was anti-rabbit (for BRN2) or anti-mouse (for 5C13, B8G3, and MART-1) Ig^HRPO conjugate diluted 1:500 in 5% skim milk powder in PBS-T for 1.5 h at room temperature followed by washes and ECL detection (Perkin Elmer Life Sciences, Wellesley, MA). The membrane was then stripped according to instructions (Perkin Elmer Life Sciences), washed in a large volume of PBS-T, and blocked again in 5% skim milk powder in PBS-T before incubation with primary antibodies to other proteins of interest as described above, or as a loading control, with anti-intermediate ¢lament protein (IFA) monoclonal supernatant (Pruss et al, 1981) being applied overnight at 41C. Following washes, anti-mouse Ig^HRPO diluted 1:500 in 5% skim milk powder in PBS-T was applied for 1.5 h, the membrane was washed, and ECL detection was performed. After each primary antibody had been detected, the membrane was stripped as described. Di¡erences in protein expression levels were determined by normalizing to IFA and subsequently the appropriate control using ImageQuant (Molecular Dynamics, Sunnyvale, CA).
Immunohistochemistry Cells were plated on to glass coverslips and allowed to attach for 36 h. Subsequently, the medium was removed and the cells were ¢xed in two changes of 4% paraformaldehyde in PBS at room temperature (10 min each). After a rinse in PBS, endogenous peroxidase activity was blocked by addition of 1% H 2 O 2 in PBS followed by 3 Â 2-min washes in PBS. The cells were subsequently blocked in 3% FBS in PBS (melanocytic markers) or 1% goat serum/0.1% Triton X-100 in PBS (for BRN2) for 20 min at room temperature before incubation with primary antibody overnight at 41C. Primary antibodies included anti-TYR 5C12, anti-TYR 5C13, and anti-TYRP1 B8G3 undiluted hybridoma supernatants; MART-1, HMB45 (Biogenex, San Ramon, CA), and chromogranin A (Biogenex) a⁄nity-puri¢ed monoclonal antibodies diluted 1:200 in 3% FBS in PBS; or 1:50 dilution of anti-BRN2C in 1% goat serum/0.1% Triton X-100 in PBS. Following 3 Â 2-min washes in PBS, immunohistochemistry was completed essentially as described (Cook et al, 2001; Leonard et al, 2002) , using a broad-spectrum Histostain-SP Kit (Zymed Laboratories, South San Francisco, CA) using avidin^biotin ampli¢cation with AEC as the chromogen. The hematoxylin counterstain was omitted for immunohistochemical analysis of BRN2.
Electrophoretic mobility shift assay Nuclear extracts were prepared from two T-75 £asks as described (Schreiber et al, 1994) , except that protease inhibitor tablets (Roche) were added to the extraction bu¡ers (Smit et al, 2000) . DNA-binding probes used were wild-type (H2B, Baumruker et al, 1988) and divergent (OA25, Bendall et al, 1993) octamer sequences, and the mutant octamer probe dpm8 . Probes were released from plasmids by overnight digestion with EcoRI and HindIII at 371C, followed by end-labeling with Klenow polymerase (New England Biolabs, Beverly, MA) using [a- 32 P]dATP and [a-32 P]dCTP. Labeled probes were puri¢ed by gel electrophoresis and 5000 cpm used in subsequent electrophoretic mobility shift assays (EMSA) with 1 mg of nuclear extract as described (Smit et al, 2000; Leonard et al, 2002) . For quantitation, the ratio of BRN2 (N-Oct-3) DNA-binding activity was normalized to Oct-1 for each lane after exposure of a phosphor screen and reading on a phosphoimager (Molecular Dynamics). This ratio was subsequently compared to the ratio obtained for primary melanocytes, with each probe being considered in isolation.
RESULTS
Establishment of primary human melanocyte and melanoblast cultures In establishing the conditions for the growth of human epidermal melanoblasts, a number of di¡erent growth factors and concentrations were examined. Preliminary experiments (Donatien et al, 1997 1 ; Donatien and Bennett, 1998 2 ), demonstrated that a medium containing a low concentration of calcium (MCDB 153; 0.03 mM Ca 2 þ ) was better than ones containing higher levels (RPMI 1640; 0.42 mM Ca 2 þ ) as this inhibited growth of any contaminating ¢broblasts. The concentration of EDN3 was best at 100 nM (range tested 1^100 nM) although there was not much increase in growth between 10 and 100 nM concentrations. Additions of FGF2 at 2.5 ng per mL and SCF at 50 to 100 ng per mL gave the best increase in growth, but culture with acceptable growth rates occurred at 10 ng per mL SCF and this was used routinely.
Melanoblast morphology and marker expression Primary human melanoblasts typically had a triangular or bipolar morphology ( Fig 1A, panel 1) , similar to that reported for murine melanoblasts (Sviderskaya et al, 1995; Kawa et al, 2000) . Like murine melanoblasts, they were unpigmented and unreactive to DOPA (Fig 1A, panel 1) , indicating lack of active TYR and consistent with the cells' having predominantly Stage I and II melanosomes as seen by transmission electron microscopy ( Fig 1B, panel 1) .When melanoblasts were cultured in melanocyte medium (MB:MC cells), the cells changed subtly to be predominantly more bipolar in morphology, typical of primary melanocytes, and became DOPA reactive to a level comparable to that of melanocyte cultures ( Fig 1A, panels 2 and 3 ). HeLa cells ( Fig 1A, panel 4) are not melanocytic and therefore are DOPAnegative and were used as a negative control. Consistent with a positive DOPA reaction, the melanosomes in MB:MC cells had matured to Stage III and IV melanosomes ( Fig 1B, panel 2 ) and resembled those of primary melanocytes (Fig 1B, panel 3) . Additionally, melanoblast cells became pigmented after 1 wk in melanocyte medium, as seen in the cell pellets ( Fig 1C) .
A number of pigmentation markers were examined by immunohistochemistry in melanoblasts, MB:MC cells, and primary melanocytes (Fig 2A) . It was found that melanoblasts express TYR, although at lower levels than in melanocytes (Fig  2A, panels 1^3 and 4^6). Localization in melanoblasts was primarily perinuclear, whereas TYR in MB:MC cells and melanocytes was dispersed throughout the cytoplasm. Immunoblot analysis showed that melanoblasts and MB:MC cells contained amounts of TYR protein similar to mature melanocytes ( Fig 2B, lanes 1^3) , suggesting that the DOPA reactivity in MB:MC cells occurred through protein activation or maturation, rather than de novo synthesis. The human melanoma cell line MM96L expressed lower amounts of TYR by immunoblot ( Fig  2B, lane 4) and MM96L c8 LC cells (Fig 2B, lane 5) served as a negative control as it had previously been shown these BRN2 ablated cells express no pigmentation markers (Thomson et al, 1995) .
In a similar manner, the distribution of TYRP1, detected using the B8G3 hybridoma (Takahashi and Parsons, 1990) in melanoblasts, was predominantly perinuclear, whereas in melanocytes and MB:MC cells, TYRP1 was distributed throughout the cytoplasm (Fig 2A, panels 7^9 ). Western blot analysis revealed that melanoblasts expressed TYPR1 at similar levels to both MB:MC cells and melanocytes (Fig 2B, lanes 1^3 ). MM96L cells expressed lower amounts of TYRP1 by Western blot analysis, and as expected, TYRP1 was not detected in MM96L c8 LC cell extracts (Fig 2B, lanes 4 and 5,  respectively) .
The HMB45 monoclonal antibody has been previously used to detect melanocytes in human skin (Holbrook et al, 1989) . The antibody recognizes the product of the silver locus, SILV (Adema et al, 1994; Kawakami et al, 1994) , mutation of which causes progressive graying of hair owing to loss of follicular melanocytes (Kwon et al, 1991 (Kwon et al, , 1995 . SILV has been implicated as having several roles in melanin synthesis, including melanosome biogenesis (Berson et al, 2001 ) and melanin stabilization and/ or polymerization (Chakraborty et al, 1996; Lee et al, 1996) . Immunohistochemical analysis of SILV expression in melanoblasts showed a perinuclear localization (Fig 2A, panels 10^12) , Recently another melanocytic protein, MART-1, has been shown to have a distinct localization from melanocytic enzymes and to decrease in level upon melanosome maturation ( De  Maziere et al, 2002) , implying a role in melanosome biogenesis. In melanoblasts, immunohistochemical analysis of MART-1 (Fig 2A, panels 13^15 ) revealed a perinuclear localization where present but not all cells were positive. Nevertheless, in both melanocytes and MB:MC cells, MART-1 localization was highly speci¢c and presented as regularly spaced foci along the length of the dendrites. MART-1 was detectable by immunoblotting (Fig 2B) in melanoblasts and MB:MC cells at similar levels, which was approximately twice that of primary melanocytes, whereas MM96L and BRN2 ablated MM96L c8 LC cells had no detectable MART-1. Chromogranin A (Fig 2A, panels 16^18 ) is a speci¢c marker for Merkel cells in human epidermis (Hartschuh et al, 1989; Leonard et al, 2002) and was used as a negative control. No immunoreactivity was seen in any cell in melanoblast, MB:MC cell, or melanocyte cultures, indicating that speci¢c reactivity had occurred with other antibodies tested.
BRN2 expression by primary human melanoblasts
Numerous transcription factors have been implicated in melanocyte development; nevertheless, given the absence of melanocytespeci¢c proteins in BRN2 ablated melanoma cell lines (Thomson et al, 1995) , we focused on the BRN2 transcription factor. Expression was analyzed by immunoblotting using anti-BRN2C polyclonal antibody (Smith et al, 1998) . BRN2 was detected in melanoblast extracts at a level similar to that of the metastatic melanoma cell line MM96L (Fig 3A, compare lanes 1  and 9) , but not in primary ¢broblasts and HeLa cells (lanes 7 and 8). Nevertheless, in MB:MC cells, expression of BRN2 decreased to a level more similar to that of primary melanocytes (Fig 3A,  compare lanes 2 and 4) , whereas melanoblasts maintained in melanoblast medium sustained high levels of BRN2 (Fig 3A,  lane 3) .
Because POU domain transcription factors bind both wildtype and divergent octamer sequences and are able to form homodimers on some sequences (Rhee et al, 1998; Smit et al, 2000) , EMSA were performed using probes containing BRN2-binding sites (Fig 3B) . The position of N-Oct-3 and N-Oct-5 (BRN2 products) DNA-binding activities were identi¢ed in MM96L extracts (Fig 3B, lanes 13^15 ) compared to the BRN2 ablated MM96L c8 LC (Fig 3B, lanes 16^18 ). All extracts contained the ubiquitous Oct-1-binding activity, and no binding to the mutant octamer probe dpm8 was seen, consistent with previous results (Thomson et al, 1995) . Results showed that melanoblasts had a typical melanocytic octamer DNA-binding pro¢le, having Oct-1 as well as N-Oct-3 and trace amounts of N-Oct-5-binding activities (Fig 3B, lanes 1^3 ) to H2B wildtype and OA25 divergent octamer sequences, with no speci¢c binding to dpm8. Relative to melanocytes (Fig 3B, lanes 7^9) , melanoblasts had more N-Oct-3 -binding activity to the H2B and OA25 probes. For MB:MC cells (Fig 3B, lanes 4^6) , however, no clear di¡erence in the N-Oct-3 activity from melanocytes was seen for either probe.
Regulation of BRN2 expression in primary human melanocyte cultures To determine the e¡ects of medium, melanocytes were cultured in melanoblast medium (MC:MB cells). After 1 wk, western blot analysis showed an increase in BRN2 to levels similar to that of melanoblasts (Fig 3A, compare lanes 6  and 1) , whereas continued melanocyte cultures retained lower levels of BRN2 (Fig 3A, lane 5) . Furthermore, MC:MB cells acquired a morphology more akin to that of melanoblast concomitant with a reduced DOPA reaction (Fig 3C) and had a reduced ability to synthesize pigment as seen by a less-pigmented cell pellet after centrifugation (Fig 3D) . When primary melanocytes were cultured in MCDB 153 (melanoblast) medium lacking SCF, FGF2, and EDN3, but supplemented with TPA, the cells remained bipolar but did not continue to grow (unpublished data). Taken together, these results imply BRN2 upregulation by growth factor(s) in the melanoblast medium or repression by factor(s) in the melanocyte medium. Interestingly, despite dramatically increased BRN2 protein levels in MC:MB cells to a level similar to that of melanoblasts (Fig 3A) , there was only a slight increase in N-Oct-3 -binding activity relative to melanocytes (Fig 3B, lanes 10^12 ). To determine whether protein localization was responsible for the slight increase in NOct-3 DNA-binding activity in MC:MB cells, immunohistochemical analysis of BRN2 was performed (Fig 3E) . Melanoblast, MC:MB cells, and MM96L cultures (Fig 3E, panels  1, 4 , and 5, respectively) all showed strong nuclear reactivity for BRN2, whereas in MB:MC cells and melanocytes (Fig 3E,  panels 2 and 3) , BRN2 was undetectable by immunohistochemistry and showed only background staining, similar to BRN2 ablated MM96L c8 LC cells (Fig 3E, panel 6 ). Hence the ability of BRN2 to bind DNA in vitro is not as e⁄cient in MC:MB cells compared to melanoblasts.
To determine which growth factor(s) were responsible for increased BRN2 in MC:MB cells, melanocytes were cultured in MCDB 153 supplemented with SCF, FGF2, or EDN3 separately, or in combination, either with or without TPA for 3 d and then harvested for western blot analysis (Fig 4A) . Compared to routine melanocyte cultures, melanocytes grown for 3 d in MCDB 153 supplemented with SCF, EDN3, and FGF2 had a dramatically increased level of BRN2 (3.5-fold, Fig 4A, lane 6) , with further upregulation when TPA was added (5.6 -fold, Fig  4A, lane 7) . Concomitant with this was a morphologic change to a polydendritic phenotype (Fig 4B, compare panel 1 (melanocyte medium) to panel 6 (melanoblast medium) and panel 7 (melanoblast medium with TPA)), consistent with that seen previously (Fig 3) . Increased BRN2 protein levels and polydendritic morphology were also observed when RPMI 1640 was supplemented with SCF, EDN3, and FGF2 (Fig 4A, lanes 4 and  5; Fig 4B, panel 4) , although not to the same extent as with MCDB 153. When melanocytes were grown in MCDB 153 supplemented with only one growth factor, BRN2 levels did not increase and actually decreased in some cases (Fig 4A, lanes  8^13) , irrespective of TPA. Interestingly, when RPMI 1640 was supplemented with FGF2 alone, BRN2 levels increased in the presence, but not absence of TPA (Fig 4A, compare lanes 2 and  3) . For melanocytes grown in MCDB 153, addition of two growth factors (SCF and EDN3, FGF2 and EDN3, or FGF2 and SCF) resulted in increased BRN2 ( Fig 4A, lanes 14^19; ratios 1. 
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.1), again regardless of TPA supplementation. Maximal increase was observed for melanocytes cultured with SCF, EDN3, and TPA (4.9-and 6.1-fold, Fig 4A, lanes 14 and 15) , whereas melanocytes cultured with FGF2 and EDN3 (Fig 4A, lanes 16 and 17) or FGF2 and SCF (Fig 4A, lanes 18 and 19) expressed lower levels of BRN2, similar to each other. It was noted that irrespective of the growth factor combination used, addition of TPA to the culture medium increased BRN2 for each combination with the exception of FGF2 and SCF. Increased BRN2 levels were also usually seen on EDN3 addition. The morphology of selected cultures assayed for total BRN2 protein levels are shown in Fig 4B. When melanocytes (Fig 4B,  panel 1) were cultured in MCDB 153 supplemented with one or two of SCF, EDN3, or FGF2 (Fig 4B, panels 8, 10, 12, 14, 16 , and 18), the cells remained bipolar. When all three growth factors were present in RPMI 1640 (Fig 4B, panel 4) or in MCDB 153, with or without TPA (Fig 4B, panels 6 and 7, respectively) an increase in the proportion of polydendritic cells in the culture was consistently observed. Hence, despite the presence of two growth factors in MCDB 153 resulting in a similar BRN2 increase similar to that obtained with all three factors, the change to a polydendritic morphology required SCF, FGF2, and EDN3.
Additionally, primary melanocytes were cultured for 3 d in melanoblast medium supplemented with two of FGF2, SCF, and EDN3, or all three factors, and then harvested for EMSA analysis (Fig 4C) to support the ¢ndings by western blot analysis. When cultured with FGF2, SCF, and EDN3, there was an increase in BRN2 DNA binding to both the H2B and OA25 probes ( Fig   4C, compare lanes 4 and 5 with lanes 1 and 2) . Interestingly, this increase is greater than the BRN2 increase observed after 7 d of culture (MC:MB cells, Fig 3B) .When melanocytes were cultured in melanoblast medium supplemented with any two of FGF2, SCF, or EDN3 (Fig 3C, lanes 7^15) , there was a slight increase in N-Oct-3 -binding activity to wild-type and divergent octamer sequences compared to melanocytes, with no binding to mutant octamer sequences.
Because MCDB 153 and RPMI 1640 di¡er greatly in the concentration of Ca 2 þ , CaCl 2 was added to MCDB 153 such that the concentration in MCDB 153 and RPMI 1640 was the same. Subsequently, melanoblasts were cultured in CaCl 2 supplemented MCDB 153 with TPA alone or SCF, EDN3, and FGF2 and then assayed for BRN2 by western blot analysis. Results showed that in CaCl 2 -supplemented MCDB 153, the addition of SCF, EDN3, and FGF2 maintained high levels of BRN2 and the polydendritic melanoblast morphology, whereas addition of TPA (and absence of peptide growth factors) resulted in decreased BRN2 protein levels and a bipolar morphology (unpublished data) similar to MB:MC cells. Additionally, supplementation of RPMI 1640 with SCF, EDN3, and FGF2 also increased BRN2 protein levels in melanocytes (Fig 4A,  lanes 4 and 5) . Hence, the presence of peptide growth factors and not the di¡erences in Ca 2 þ between the media is responsible for the di¡ering BRN2 levels.
N-Oct-3 activity in murine neural crest To determine whether primary neural crest cells express BRN2, retrovirally transformed murine cell lines established from isolated trunk neural tubes of 9 d postcoitum embryos (Murphy et al, 1991) as well as mouse brain and MM96E melanoma cell nuclear extracts were assayed by EMSA for octamer DNA-binding activity. Oct-1 DNA-binding activity was detected in all extracts examined ( Fig  5A) . Strong N-Oct-3 and N-Oct-5 activity was seen in the MM96E melanoma cell line extract (Fig 5A, lane 3) , whereas mouse brain had lower N-Oct-3 activity (Fig 5A, lane 1) . Of the neural crest cultures examined, NC 14.3.3G, NC 14.4.9D, NC 14.4.8, and NC 14.4.6E had detectable N-Oct-3 -binding activity A2058 (lanes 1^3) and mouse brain (lanes 13^15) octamer pro¢les to the OA25 (lanes 2 and 3, 5 and 6, 8 and 9, 11 and 12, and 14 and 15) and dpm8 (lanes 1, 4, 7, 10, and 13) were included for comparison purposes. Positions of the Oct-1, BRN2 (N-Oct-3) and BRN2 (N-Oct-5) complexes are indicated. Inclusion of anti-BRN2 POU domain antibody was used for con¢rmation of N-Oct-3 and N-Oct-5 complexes (supershift indicated by arrowhead). FP, free probe.
( Fig 5A, lanes 5, 11, 13, and 15, respectively) . Two of these cell lines, NC 14.4.9D and NC 14.4.6E, have been classi¢ed as ''differentiated'' cell lines, whereas NC 14.4.8 are considered ''partially di¡erentiating'' cells and NC 14.3.3G as an ''undi¡erentiated'' neural crest-like cell type (Murphy et al, 1991) .
Further to this, Reid et al (1995) demonstrated that Kit-positive cells in neural crest cultures were precursors of melanocytes and that addition of TPA resulted in cell pigmentation. Hence, we examined primary neural crest cultures of Kit-negative, Kitpositive, unpigmented and Kit-positive, pigmented cells using mouse brain and A2058 melanoma cell extracts as controls for N-Oct-3 DNA-binding activity. The A2058 melanoma cells (Fig 5B, lanes 1^3 ) contained the Oct-1, N-Oct-3, and N-Oct-5 DNA-binding activities. The N-Oct-5 complex was detected in all three neural crest cultures, whereas N-Oct-3 was not apparent (Fig 5B, lanes 4^12) . The N-Oct-5 protein has been speculated to arise from proteolytic clipping of the N-Oct-3 protein (Atanasoski et al, 1997; Smith et al, 1998) and its presence in less di¡erentiated primary melanoma cell lines prompted speculation that it may play a role in the di¡erentiation process during melanocyte development. Inclusion of an anti-BRN2C antibody resulted in a supershift of the N-Oct-5 complex, indicating that the protein complex detected contained a BRN2 gene product.
DISCUSSION
Melanoblasts are a neural-crest-derived cell type de¢ned as speci¢ed melanocyte precursors which are unable to synthesize melanin (Hirobe, 1992; Sviderskaya et al, 1995) . Here, we have described conditions for culturing human melanoblasts. We have shown that they are unpigmented cells containing immature melanosomes that are unreactive to DOPA (Fig 1) . This is despite human melanoblasts expressing TYR and TYRP1 protein, unlike murine melanoblasts in which Tyr was detected in only a minority of cells by immunohistochemistry (Sviderskaya et al, 1995; Kawa et al, 2000) . Examination of the POU domain transcription factor BRN2, implicated in di¡erentiation of the melanocytic lineage (Eisen et al, 1995; Thomson et al, 1995) , demonstrated that melanoblasts expressed high levels of BRN2 protein and N-Oct-3 DNA-binding activity, similar to metastatic melanoma cell lines and at a much higher level than melanocytes (Fig 3) . Presumably, the lower relative fold increase in N-Oct-3 activity compared to the increase in total BRN2 protein is due to a number of factors including normalization to di¡erent proteins and inherent di¡erences between western blot analysis and DNAbinding assays. We have shown that BRN2 localization is not the reason for these di¡erences (Fig 3E) . Nevertheless, in all experiments, changes in BRN2 protein levels followed the same qualitative trends as N-Oct-3 DNA-binding activity.
Upon change of growth factor supplementation, we were able to induce primary human melanoblasts to become DOPA-positive and furthermore acquire the ability to synthesize melanin owing to melanosome maturation as determined by transmission electron microscopy (MB:MC cells, Fig 1) . Concomitant with this was a change in cell morphology to one resembling that of melanocytes ( Fig 1A) and a decrease in BRN2 to levels similar to those of melanocytes (Fig 3A) . Given the similarities between MB:MC cells and melanocytes, and the de¢nition of a melanoblast (Sviderskaya et al, 1995) , we consider MB:MC cells to be melanocytes and that melanoblasts have been induced to di¡er-entiate in vitro by the change in culture conditions.
Further to this, culture of melanocytes in melanoblast medium (MC:MB cells) produced a decrease in DOPA reactivity and melanin synthesis, a change in morphology, and an increase in BRN2 protein and DNA-binding activities (Fig 3) . Hence, MC:MB cells are very similar to melanoblasts, and we interpreted this as a dedi¡erentiation of melanocytes in response to medium changes. It is interesting to note that avian melanocytes cultured with EDN3 have been reported to revert to a bipotent progenitor cell capable of redi¡erentiation to melanocytes (Dupin et al, 2000) . Furthermore, avian Schwann cells cultured with EDN3 revert to a bipotent glial-melanocyte precursor cell population able to di¡erentiate into melanocytes (Dupin et al, 2003) . It was not reported, however, whether the dedi¡erentiation of avian melanocytes and glial cells seen with EDN3 resulted in an increase in BRN2, similar to the dedi¡erentiation of melanocytes seen here.
To elucidate which growth factors were responsible for the increase in BRN2 protein, melanocytes were grown with several combinations of growth factors and then assayed for BRN2 protein. This revealed a possible synergistic mechanism controlling BRN2, requiring at least two of SCF, FGF2, and EDN3 to increase BRN2 protein levels in MCDB 153, irrespective of the presence of TPA. Endothelin-1 and SCF can act synergistically to enhance proliferation of human melanocyte cultures via transactivation of the Kit receptor leading to activation of mitogenactivated protein kinase (Imokawa et al, 2000) , with Kit-activated mitogen-activated protein kinase increasing the transcriptional activity of microphthalmia associated transcription factor (Hemesath et al, 1998) by speci¢cally recruiting p300 . Because BRN2 is also capable of interacting with p300 (Smit et al, 2000) , it is possible that EDN3 and SCF can interact in a similar manner to endothelin-1 and SCF, with the outcome being increased production and/or transcriptional activity of BRN2. Synergism between SCF and EDN3 has been previously reported to enhance murine melanocyte precursor proliferation and survival in culture (Reid et al, 1996) . Furthermore, disruption of either signaling mechanism in vivo causes severe loss of melanoblasts in mouse (Steel et al, 1992; Pavan and Tilghman, 1994; Wehrle-Haller and Weston, 1995) underlying the importance of BRN2 in melanocytic cells.
Other POU domain transcription factors are downregulated upon di¡erentiation of speci¢c cell types in vivo and in vitro. For instance, the Class III factor Oct-6/Tst-1/SCIP (also POU3F1) is expressed in glial cell progenitors of both the central and the peripheral nervous system (Collarini et al, 1992; Jaegle et al, 1996) and the embryonic POU domain factor Oct-3/4 (POU5F1) is expressed by ES cells (Niwa et al, 2000; Reubino¡ et al, 2000) , but are downregulated as the cells di¡erentiate. Similar to BRN2 in melanoma, Oct-3/4 is upregulated again in cancer cell lines (Monk and Holding, 2001) . Interestingly, the neural-crest-derived peripheral nervous system glial cell, the Schwann cell, expresses the cell-type-speci¢c transcription factors SOX10 and PAX3 (also expressed by melanocytes) in addition to BRN2 and grows in vitro as a dendritic cell similar to melanocytes (reviewed in Jessen and Mirsky, 1998) , consistent with the existence of a melanocyteĝ lial bipotent progenitor cell (Le Douarin and Kalcheim, 1999) . Notably, Schwann cell demyelination owing to nerve injury causes an upregulation of BRN2, which remains until the nerve remyelinates (Sim et al, 2002) , suggesting that BRN2 is upregulated owing to cellular stress or Schwann cell proliferation.
BRN2/N-Oct-3 DNA-binding activity was also detected in murine neural crest cultures (Fig 5) . The NC 14.3.3G cell line had high levels of N-Oct-3 and has been classi¢ed as an ''undifferentiated'' neural crest-like cell type, because it expresses no markers speci¢c for terminally di¡erentiated neurons or glia (Murphy et al, 1991) , suggesting that BRN2 is expressed early in neural crest cell segregation. Interestingly, the NC 14.4.9D cell line which was classi¢ed as a ''di¡erentiated'' cell type, but was considered bipotent owing to expression of both Schwann cell and neuronal markers (Murphy et al, 1991) , has N-Oct-3 activity (Fig 5) . Additionally, NC 14.4.9D has a strong mitogenic response to FGF2, and a dendritic morphology similar to melanocytes and Schwann cells (Murphy et al, 1991) , and hence NC 14.4.9D may represent a bipotent glia^melanocyte progenitor cell (Le Douarin and Kalcheim, 1999) . N-Oct-3 activity has also been detected in neural-crest-derived carcinoma cell lines, such as small cell lung carcinomas, Merkel cell carcinomas, astrocytomas, glioblastomas, and Ewing's sarcomas (Schreiber et al, 1992; Schreiber et al, 1994; Thomson et al, 1994; Leonard et al, 2002) suggesting BRN2 involvement in the development of multiple neural crest lineages.
In conclusion, we have shown that human cultured melanoblasts express BRN2 at high levels comparable to melanoma cell lines and that this level decreased on di¡erentiation to melanocytes. This supports the involvement of BRN2 in maintenance of the melanoblast phenotype and a reciprocal impairment of melanocyte maturation. The £exible DNA recognition and homodimerization properties of BRN2 in melanocytic cells (Rhee et al, 1998; Smit et al, 2000) make the levels of this protein critical and may allow it to act as both an activator and a repressor of melanocytic gene expression patterns mediating cell fate transitions.
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